# Oberland Capital

> Oberland Capital is a VC fund backing Health Care and Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 24
- Last investment: Aug 2026
- Lead investor: 88%
- Fund size: $1.2B
- Last fund: Oct 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/oberland-capital
- Website: http://www.oberlandcapital.com/

Oberland Capital is a VC fund in New York focused on Health Care and Biotechnology. Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry. We specialize in flexible investment structures customized to meet the specific capital requirements and strategic objectives of transaction partners globally. Our broad suite of financing solutions includes monetization of royaltystreams, acquisition of future product revenues, creation of project-based financing structures, and investment in debt and equity securities. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for our transaction partners.

## Contacts

5 contacts available for Oberland Capital. Shizune tracks 4 team members at Oberland Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/oberland-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 50% |
| Biotechnology | 12 | 50% |
| Pharmaceutical | 9 | 38% |
| Therapeutics | 6 | 25% |
| Biopharma | 3 | 13% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 8 | 33% |
| Post-IPO Equity | 8 | 33% |
| Series A | 1 | 4% |
| Series B | 1 | 4% |
| Funding Round | 1 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 54% |
| Denmark | 1 | 4% |
| Switzerland | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cecilia Gonzalo | Partner | 0 | — |
| Jean-Pierre Naegeli | Managing Partner & FOUNDER | 0 | — |
| Michael Bloom | Partner | 0 | — |
| William Clifford | Partner | 3 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Verastem Oncology | Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. | $50M | Post-IPO Debt | Aug 06, 2026 |  |
| MeiraGTx | MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders.The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarilyrevolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. | $125M | Post-IPO Debt | Jul 07, 2026 |  |
| MeiraGTx | MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders.The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarilyrevolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. | $10M | Post-IPO Equity | Jul 07, 2026 |  |
| Opus Genetics(formerly Ocuphire Pharma) | Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $35M | Post-IPO Debt | Apr 06, 2026 |  |
| Opus Genetics(formerly Ocuphire Pharma) | Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $5M | Post-IPO Equity | Apr 06, 2026 |  |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $23.3M | Series B | Jan 26, 2026 |  |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $23.3M | Series B | Jan 26, 2026 |  |
| ClearPoint Neuro | ClearPoint Neuro formerly known as MRI Interventions, is a platform neuro company. Its mission is to improve and restore the quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ClearPoint Neuro's current product portfolio include deep-brainstimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. | $20M | Post-IPO Debt | Nov 20, 2025 |  |
| ClearPoint Neuro | ClearPoint Neuro formerly known as MRI Interventions, is a platform neuro company. Its mission is to improve and restore the quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ClearPoint Neuro's current product portfolio include deep-brainstimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. | $3.5M | Post-IPO Equity | May 12, 2025 |  |
| ClearPoint Neuro | ClearPoint Neuro formerly known as MRI Interventions, is a platform neuro company. Its mission is to improve and restore the quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ClearPoint Neuro's current product portfolio include deep-brainstimulation, and biopsy, with future applications of laser ablation, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. | $30M | Post-IPO Debt | May 12, 2025 |  |

10 of 24 investments shown.

## Co-investors
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 3 deals together
- [Bioqube Ventures](https://shizune.co/investors/profile/bioqube-ventures) — VC Fund, 2 deals together
- BioBrit — VC Fund, 1 deal together
- BioRock Ventures Name — VC Fund, 1 deal together
- [CAM Capital](https://shizune.co/investors/profile/camcapital) — VC Fund, 1 deal together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Oberland Capital invest in?

Oberland Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Post-IPO Debt and Post-IPO Equity stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Oberland Capital?

Public channels for Oberland Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Oberland Capital?

The team at Oberland Capital includes Cecilia Gonzalo (Partner), Jean-Pierre Naegeli (Managing Partner & FOUNDER) and Michael Bloom (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co